Any prior therapy must have been completed >= 4 weeks or, if known, >= 5 half-lives of the prior agent (whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment), and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least 6 weeks out from nitrosoureas and mitomycin C; prior definitive radiation should have been completed >= 4 weeks or palliative radiation should have been completed >= 2 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels (patients on study may be eligible for palliative radiotherapy to non-targeted lesions after 2 cycles of therapy at the principal investigator [PI]’s discretion); patients who have had prior monoclonal antibody therapy must have completed that therapy >= 6 weeks (or 3 half-lives of the antibody, whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment); patients who have received more than a cumulative dose of 350 mg/m^2 of doxorubicin may be enrolled at the discretion of the coordinating center PI, with a screening echocardiogram
Enrolled on SJMB12 and completed protocol directed radiation therapy
All adjuvant or neoadjuvant chemotherapy, radiation, and surgery completed at least 21 days prior to registration\r\n* All triple negative patients must receive chemotherapy of the treating physician’s choice\r\n* ER/PR+ patients must receive chemotherapy (of the treating physician’s choice) unless Oncotype Dx or another genomic predictor score indicates that they are at low or intermediate risk of disease recurrence with endocrine therapy alone\r\n* Patients may have breast reconstruction during protocol participation, but definitive breast cancer surgery must be completed at least 21 days prior to registration\r\n** Concomitant biologic therapy, hormonal therapy, and bisphosphonates are acceptable
Patients must have completed any prior radiation therapy and hormonal therapy at least 14 days prior to registration
Any prior surgeries must have been completed at least 4 weeks prior to randomization
Any prior chemotherapy (based on administration schedule) must have been completed in greater than or equal to the following times prior to registration:\r\n* Chemotherapy/ targeted oral therapy administered in a daily or weekly schedule must be completed >= 1 week prior to registration; \r\n* Any chemotherapy administered in an every 2 week or greater schedule must be completed >= 2 weeks prior to registration\r\n* Additionally, patients should be recovered to equal to or less than grade 1 Common Terminology Criteria for Adverse Events (CTCAE) v5.0 from toxicities related to any prior treatment, unless adverse event (AE)(s) are clinically nonsignificant and/or stable on supportive therapy
Prior ipilimumab treatment with the exception of adjuvant treatment completed ?6 months prior to enrollment
Must have completed definitive treatment that included surgical removal of the clinically detected MCC metastases (with/without adjuvant radiation therapy as determined by the treating investigator)
History of prior cancers except for those that have been curatively treated, with no evidence of cancer currently (provided all chemotherapy was completed >6 months prior and/or bone marrow transplant >2 years prior to first dose of rucaparib).
Prior treatment including chemoembolization or other ablative therapy, any cytotoxic, biologic or other investigational agents must have been completed at least 4 weeks prior to study entry
Previous chemotherapy/radiotherapy/targeted therapy should have been completed at least 4 weeks prior to start of FID-007 administration
Subjects must have completed systemic therapy at least 28 days prior to first dose.
Any prior therapy must have been completed >= 4 weeks (6 weeks for nitrosoureas and mitomycin C) or, if known, >= 5 half-lives of the prior agent (whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment), and the participant must have recovered to eligibility levels from prior toxicity; prior definitive radiation should have been completed >= 4 weeks or palliative radiation should have been completed >= 2 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (where a sub-therapeutic dose of drug is administered) at the principal investigator's (PI’s) discretion, and should have recovered to grade 1 or baseline from any toxicities
Previous immunotherapy/monoclonal antibody use must be completed at least 4 weeks or 4 half lives, whichever is longer prior to administration of TAK-580; in addition, radiation therapy to the target lesion must be completed at least 6 months prior to administration of TAK-580; all associated toxicity from previous therapies must be resolved to ? grade 1 or considered baseline prior to administration of TAK-580
Prior antitumor therapy that is not completed at least 4 weeks prior to first dose of study drug, or at least 2 weeks if progressing. Prior CAR T-cell therapy must be completed 8 weeks before first dose of study drug.
Prior radiotherapy or radiosurgery (including prophylactic cranial radiation and/or thoracic radiation) must have been completed at least 2 weeks prior to randomization
PHASE II INCLUSION CRITERIA: Prior radiotherapy or radiosurgery (including prophylactic cranial radiation and/or thoracic radiation) must have been completed at least 2 weeks prior to randomization
Prior systemic radiation therapy (either IV, intrahepatic or oral) completed at least 4 weeks prior to study drug administration.
Prior focal radiotherapy completed at least 4 weeks prior to study drug administration.
Platelets >= 100,000/microliters, completed within 14 days prior to the date of registration
Participants must have known HIV infection and histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; any number of prior cancer therapies will be permitted; at least 4 weeks must have elapsed since prior chemotherapy or biological therapy, 6 weeks if the regimen included carmustine (BCNU) or mitomycin C; prior radiation therapy to the thoracic cavity, abdomen, or pelvis must be completed at least 3 months prior to registration; radiotherapy to any other site (including bone or brain metastases) must be completed at least 28 days prior to registration
Previous radiation therapy completed =< 7 days prior to the start of study drugs
Prior radiation therapy is allowed as long as the irradiated area was not the sole source of measurable disease and radiotherapy was completed with recovery from toxicity, at least 3 weeks prior to enrollment; if the irradiated area is the only site of disease, there will be progressive disease
Prior radiation therapy is allowed as long as the irradiated area was not the sole source of measurable disease and radiotherapy was completed with recovery from toxicity, at least three weeks prior to enrollment; if the irradiated area is the only site of disease, there must be evidence of progressive disease
Prior radiation therapy must be completed >= 2 weeks prior to enrollment and the patient must have recovered from all toxicity; prior radiopharmaceuticals (strontium, samarium, alpharadin) must be completed >= 4 weeks prior to enrollment
Prior radiation therapy must be completed at least 14 days prior to registration for protocol therapy
Patients who have completed focal radiotherapy within 14 weeks from time of enrollment are eligible.
Time from prior therapy:\r\n* Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter (6 weeks for nitrosoureas or mitomycin C)\r\n* Hormonal therapy is not considered anti-neoplastic therapy\r\n* Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
Prior therapy, including everolimus, octreotide, surgery, chemoradiation, is all permitted after being properly noted; this prior therapy must have been completed at least 28 days prior to study enrollment
Must have completed prior chemotherapy or radiation therapy at least 2 weeks prior to registration
Subjects may have previously treated brain or central nervous system (CNS) metastasis with radiation completed at least 2 weeks prior to registration; prior radiation to places other than CNS disease must be completed at least 14 days prior to registration; any number of prior radiation therapy regimens is allowed provided all toxicity of prior therapy is resolved to grade 1 or less.
Any prior therapy must have been completed at least 4 weeks prior to entry into the study
Prior radiation therapy is permitted, provided it is completed at least 28 days prior to the start of study drug
Prior radiation therapy must be completed at least 2 weeks prior to study enrollment
Prior chemotherapy, monoclonal antibody therapy, must have been completed at least 4 weeks prior to start. Radiotherapy or radiosurgery must have been completed at least 2 weeks prior to start.
Patients who have received radiation therapy must have completed this at least 4 weeks prior to starting therapy with cabozantinib, with the following exceptions:\r\n* Local radiation therapy to enhance bone healing of a pathologic fracture may have been performed, as long as it was completed at least 2 weeks prior to starting cabozantinib\r\n* Local radiation therapy to treat post-fracture pain that is refractory to analgesics may have been performed, as long as it was completed at least 2 weeks prior to starting cabozantinib
Prior systemic chemotherapy or other investigational therapy must have been completed at least two weeks prior to administration of nivolumab
(For cohort A only): Time from prior therapy: a. Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter. Hormonal therapy is not considered anti-neoplastic therapy. b. Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
Prior radiation therapy is allowed if completed at least 14 calendar days prior to registration
Prior cetuximab permitted if it was given for no more than 9 doses in combination with radiation therapy or chemoradiation therapy for initial treatment of locally advanced or metastatic disease and completed at least 4 months prior to study enrollment
Previously received at least one line of prior systemic therapy for metastatic disease; if the patient has a sensitizing EGFR mutation or ALK rearrangement, the patient must have received at least one prior targeted therapy for metastatic disease (ie, EGFR tyrosine kinase inhibitor [TKI] therapy or ALK TKI therapy, respectively); there is no limit on prior therapies allowed; patients must have completed previous treatment (including other investigational therapy) in greater than or equal to the following times prior to initiation of trial treatment:\r\n* Anti-cancer monoclonal antibody (mAb) therapy must be completed >= 3 weeks prior to trial treatment\r\n* Chemotherapy administered in a daily or weekly schedule must be completed >= 1 week prior to trial treatment\r\n* Chemotherapy administered in an every 2-week schedule must be completed >= 2 weeks prior to trial treatment\r\n* Chemotherapy administered in an every 3-week schedule must be completed >= 3 weeks prior to trial treatment\r\n* Targeted small molecule therapy must be completed >= 1 week prior to trial treatment OR\r\n* Have not received prior systemic therapy for their cancer in recurrent or metastatic setting, AND have a tumor with tumor proportion score (TPS) >= 50% as measured by 22C3 PD L1 immunohistochemistry (IHC) test, AND no evidence of a sensitizing EGFR mutation or ALK rearrangement
Patients who have had cranial radiation therapy need to have completed it >= 8 weeks prior to enrollment
Radiotherapy completed within 2 weeks prior to treatment initiation; radiotherapy completed > 2 weeks prior to treatment initiation is allowed if all procedure-related toxicities resolved
Participants in cohort D must have completed systemic therapy AND have completed either consolidation thoracic radiotherapy or PCI or both completed either consolidation thoracic radiotherapy or PCI or both; participants in cohort D must initiate therapy with pembrolizumab within 6 weeks of the last dose of radiation; therapy must not start within 2 weeks from the last dose; consolidation radiotherapy dose must NOT be more than 3000 cGy; participants in cohort D must not have had progression of disease prior to the start of therapy
Prior radiotherapy completed <28 days before study enrollment.
Any prior chemotherapy, immunotherapy, radiation therapy or surgeries must have been completed at least 3 weeks prior to initiation of study medication.
Prior locoregional therapy is allowed if completed at least 2 weeks prior to enrollment
Prior chemotherapy is allowed if stopped/completed at least 2 weeks prior to enrollment
Radiation therapy must be completed at least 2 weeks prior to study entry; radiated lesions may not serve as measurable disease unless they have been radiated >= 12 months prior to enrollment
Radiation therapy with >= 45 Gy tumor dose, completed >= 8 weeks prior to study entry
Prior therapy(ies), if applicable, must be completed according to the criteria below:
All patients must have completed any prior chemotherapy, targeted therapy, radiotherapy (unless palliative doses which must be discussed with study principal investigator), surgery, anti-angiogenic therapy or interferon >= 28 days before study entry
Patients should not have received prior systemic therapy for metastatic RCC; prior radiotherapy must have been completed at least 2 weeks prior to the administration of study drug; patients must be 2 weeks from prior major surgery and 1 week from pre-treatment biopsy; prior systemic adjuvant therapy (excluding with PD1 or CTLA4 pathway blockers) is allowed if treatment completed > 12 months previously
Previous treatment: prior systemic anti-cancer treatment consisting of chemotherapy, immunotherapy, or targeted therapy are allowed provided therapy completed at least 1 year prior to enrollment\r\n* No prior talimogene laherparepvec or tumor vaccines allowed\r\n* No prior radiation to the same tumor bed allowed
Subject has any acute infection that requires specific therapy; acute therapy must have been completed within seven days prior to study enrollment
Patient must have completed any systemic therapy regimens (except an ALK inhibitor) and therapeutic radiation a minimum of 21 days prior to initiation of study therapy
Patients must have failed external beam radiotherapy >= 5,000 cGy to the brain, and if eligible and tolerated, undergone appropriate treatment with temozolomide chemotherapy; all radiation and additional chemotherapies must have been completed at least 4 weeks prior to enrollment; prior therapy with nitrosoureas must have been completed at least 6 weeks prior to enrollment
Prior radiation therapy completed >= 4 months, and/or chemotherapy completed >= 1 month before study entry, and patient should have recovered from any adverse effects
Patients must have had at least one prior chemotherapeutic regimen; steroids alone and local radiation do not count as regimens; radiotherapy must have been completed at least 4 weeks prior to entry into the study; Rituxan alone does not count as a regimen; however, Bexxar or Zevalin (ibritumomab tiuxetan) do and patients must have completed radioimmunotherapy (RIT) > 12 months prior to enrollment
Completed all prior therapies (immunosuppressive medications, antineoplastic therapy, vaccination, immunotherapy, chemotherapy, radiotherapy, major surgery, etc) >4 weeks prior to the first study dose of medication (alemtuzumab ? 6 months).
PART II: All eligibility requirements and exclusion criteria as described in PART 1 must be fulfilled within 14 days of receiving subsequent doses; testing completed from Part 1 may be accepted as long as completed within this time frame (+/- 1 day)
radiation therapy (gamma knife) was completed ? 4 weeks prior to baseline
surgery was completed ?4 weeks prior to baseline
Prior cancer therapy with pemetrexed/cisplatin must have been completed at least 30 days prior to the first cycle of milataxel; prior radiotherapy (less than 25% of the bone marrow) must have been completed at least 30 days prior to study enrollment.
Prior cancer therapies not completed within 30 days prior to the first cycle of milataxel; radiotherapy completed less than 30 days prior to study enrollment; patients not recovered from radiation-related toxicities; patients receiving any concurrent anti-cancer therapy, including trastuzumab, bevacizumab or an investigational agent while on-study; patients with greater than 2 prior radiotherapy treatments.
Completed standard therapy ( at least 3 months of chemotherapy ± radiotherapy )
Completed the following investigations
Completed radiotherapy, chemotherapy, and/or treatment with other investigational agents at least 3 weeks prior to study entry
Have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug
Prior anti-cancer therapy or radiation therapy within 2 weeks prior to enrolment. Palliative radiotherapy to metastatic lesion(s) permitted providing that it has been completed at least 2 days prior to enrolment and no significant toxicity are expected.
Previous radiation therapy completed =< 7 days prior to the start of study drugs
Active infection; any systemic antimicrobial therapy must be completed >= 5 days prior to initiation of protocol therapy
Patient has completed radiotherapy within 2 weeks prior to treatment initiation.
Subjects have any acute infection that requires specific therapy. Acute therapy must have been completed within seven days prior to study enrollment.
Completed planned breast surgeries and any radiation therapy >= 30 days prior to randomization
All prior systemic cancer therapy (hormonal, chemotherapeutic, and immunotherapeutic) must be completed at least 4 weeks before the baseline visit
All previous chemotherapy or radiation must be completed at least 3 weeks prior to study entry; immunologic therapy must be completed at least 1 week prior to study entry; patients with prior stem cell transplant must be greater than 365 days post-transplant
Patients must have a histologic diagnosis of melanoma either from a primary or metastatic site; patients with brain metastases must have completed radiation therapy > 30 days prior to enrollment
Patients with a history of malignancy that has been completely treated, with no\n             evidence of that cancer currently, are permitted to enrol in the trial provided all\n             chemotherapy was completed greater than 6 months prior and/or bone marrow transplant\n             greater than 2 years prior
Patients must have successfully completed therapy with sipuleucel-T within 3-7 days of planned CYT107 study drug treatment
Prior “systemic” radiopharmaceuticals (strontium, samarium, radium 223 dichloride) must be completed >= 8 weeks prior to enrollment
Patients must be completed radiation therapy at least 4 weeks previously
Any exogenous hormone therapy must be completed 4 weeks prior to registration
Patients with prior radiation therapy completed less than 4 weeks prior enrollment
Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events have either returned to baseline or stabilized\r\n* For the fourth cohort, ipilimumab at 3 mg/kg must have been completed not less than 4 weeks prior to initiation of BMS-936558; ipilimumab at 10 mg/kg must have been completed not less than 6 weeks prior to initiation of BMS-936558\r\n* All drug related toxicities must have resolved to grade 1 or less, and patients must be off steroids for at least 3 weeks\r\n* Patients in the fourth cohort who required infliximab or other immune suppressants including mycophenolic acid will be excluded\r\n* For the fifth cohort, ipilimumab at 3 mg/kg or 10 mg/kg must have been completed not less than 8 weeks prior to initiation of BMS-936558; all drug related toxicities must have resolved to grade 1 or less, and patients must be off steroids for at least 2 weeks and any other immune suppressant such as mycophenoloc acid or infliximab for at least 3 weeks\r\n* Patients in the fifth cohort who experienced grade 3-4,neurologic or ophthalmologic side effects or any other grade 4 side effect other than liver, pancreatic, gastrointestinal (GI), endocrine, pulmonary or skin related will be excluded
Has completed a prior therapy (ies) according to the criteria below:
Patient has completed adjuvant radiotherapy (if indicated) prior to screening
Patients must have completed their last chemotherapy regimen > 4 weeks prior to treatment initiation.
Non-CNS site of radiation must be completed > 2 weeks prior to CTL019 infusion
Will have completed the first line chemotherapy regimen completed at least 14 days prior to initiation of 2nd line chemotherapy under the protocol
REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have completed chemoradiotherapy per protocol and at least four weeks but no more than six weeks must have elapsed from the last day of induction therapy (the last day of radiation)
Prior systemic, regional and radiation anticancer therapies for melanoma must have been completed at least 3 months prior to randomization.
Completed last cycle of chemotherapy or radiation > 60 days prior to first vaccination
Prior therapy(ies), if applicable, must be completed according to the criteria below prior to first dose of tazemetostat:
Prior radiotherapy must be completed at least 4 weeks before patient begins study therapy.
Patient must have not received systemic chemotherapy for metastatic disease; prior chemotherapy, radiation therapy, concurrent chemoradiation are allowed if used for treatment of non-metastatic disease; prior palliative radiation for symptom management is allowed; any chemotherapy must have been completed 4 weeks prior to enrollment; any radiotherapy must have been completed 2 weeks prior to enrollment
Must have completed definitive resection of primary tumor. The last surgery for breast cancer must have been completed at least 14 days prior to registration for protocol therapy.
Prior chemotherapy must have been completed 21 days prior to initiation of protocol therapy and all toxicities must < grade 2.
Patients must have completed initial radiation therapy (RT) and temozolomide (TMZ) for the treatment of their glioblastoma (i.e., completed 6-week course of RT and, completed >= 75% of 6-week course of induction TMZ chemotherapy)
Any chemotherapy must have been completed 4 weeks prior to enrollment
Any radiotherapy must have been completed 2 weeks prior to enrollment
Subject agrees to refrain from blood donations during therapy on study and for 8 weeks after therapy is completed
Patients must have previously received at least one line of prior systemic chemotherapy or targeted treatment for metastatic disease OR have received prior adjuvant systemic chemotherapy within prior 6 months; patients with MBC, must have received at least a taxane based regimens; patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK) mutations should have failed prior standard tyrosine kinase inhibitor (TKI) therapy; patients must have completed previous treatment (including other investigational therapy) in greater than or equal to the following times prior to initiation of study treatment:\r\n* Chemotherapy/targeted therapy administered in a daily or weekly schedule must be completed >= 2 weeks prior to study treatment \r\n* Chemotherapy/targeted therapy administered in a 2-weekly schedule must be completed >= 3 weeks prior to study treatment\r\n* Chemotherapy/targeted therapy administered in a 3-weekly or greater schedule must be completed >= 4 weeks prior to study treatment
Patients must not have received prior systemic therapy for their advanced cancer; prior intravesical therapy completed 4 weeks prior to enrollment and adjuvant/neoadjuvant chemotherapy completed more than 6 months prior to diagnosis of advanced disease are permitted
Prior anti-cancer therapy within 4 weeks prior to study enrollment. Prior radiation therapy within 2 weeks prior to enrollment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed 2 days prior to study enrollment and no clinically significant toxicities are expected (eg, mucositis, esophagitis).
Any prior chemotherapy, immunotherapy or targeted therapy must have been completed at least 2 weeks prior to start of this protocol and all side effects (except alopecia, lymphopenia and hyperglycemia) resolved to grade 1 or less; any prior radiation must have been completed at least 2 weeks prior to start of therapy
Any prior chemotherapy, immunotherapy or targeted therapy must have been completed at least 4 weeks prior to start of this protocol and all side effects (except alopecia, lymphopenia and hyperglycemia) resolved to grade 1 or less; any prior radiation must have been completed at least 2 weeks prior to start of therapy
Patients may have received therapy for other malignancies, as long as they have completed therapy at least 6 months prior to study entry and be deemed to have a life expectancy of at least 2 years with regard to that malignancy
Prior treatment (somatostatin analogs excepted) must be completed at least 2 weeks prior to registration; in addition, prior treatment (somatostatin analogs excepted) must be completed at least 4 weeks prior to initiation of study drug; treatment-related toxicities must have improved to =< grade 1 prior to registration, with the exception of alopecia
Prior systemic anti-cancer therapy, unless administered for localized SCCHN and completed at least 6 months prior to disease recurrence
Patients must have completed any prior radiotherapy at least 2 weeks prior to initiation of protocol therapy
Prior radiation therapy must be completed > 4 weeks prior to enrollment and the patient must have recovered from all toxicity. Prior radiopharmaceuticals (strontium, samarium) must be completed ? 8 weeks prior to enrollment.
Patients must have been treated previously with radiation therapy and treatment must have been completed at least 8 weeks prior to surgery for catheter implantation
prior immunotherapy, or prior investigational agents should be washed out 4 weeks before apheresis and must be completed 4 weeks prior to pre-infusion lymphodepletive chemotherapy.
Systemic corticosteroid or other immunosuppressive therapy should be washed out 2 weeks before apheresis and must be completed at least 2 weeks prior to pre-infusion lymphodepletive chemotherapy
Radiation therapy to brain for DIPG that was completed at least 10 months prior to planned reirradiation
Prior radiotherapy must have been completed at least 2 weeks prior to study entry For Arm M:
Previous chemotherapy, immunotherapy, and hormone therapy must be completed at least 4 weeks prior to the administration of MLN2480 and radiation must be completed at least 3 weeks prior to the administration of MLN2480; all associated toxicity must be resolved to ? Grade 1
All standard tumor-staging procedures necessary to define baseline extracranial disease status completed =< 42 days prior to pre-registration
Completed cancer specific therapy at most 6 months prior to entry
Prior experimental systemic therapies must have been completed greater than 2 weeks prior to study entry
Any prior radiation therapy must be completed at least 4 weeks prior to registration
Subject may have received prior radiation therapy (except to inguinal region) but must have completed such therapy prior to enrollment
Subject has any acute infection that requires specific therapy; acute therapy must have been completed within seven days prior to study enrollment
Chemotherapy or trastuzumab or bevacizumab in the adjuvant setting is allowed but must have been completed at least 4 weeks prior to study registration; other prior non-hormonal investigational agents in the adjuvant setting must have completed at least 4 weeks prior to study registration and should be discussed with the study principal investigator (PI)
Any prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least six weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an “early phase I study” or “pre-phase I study” where a sub-therapeutic dose of drug is administered) at the PI’s discretion, and should have recovered to eligibility levels from any toxicities
Any prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least 6 weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an “early phase I study” or “pre-phase I study” where a sub-therapeutic dose of drug is administered) at the principal investigator's (PI’s) discretion, and should have recovered to eligibility levels from any toxicities
Completed the End of Study Visit in Study NEOD001-201
Radiation therapy was completed on the index vertebra(e) ? 28 days before enrollment,
Patients with a history of malignancy that has been completely treated, and currently with no evidence of that cancer, are permitted to enroll in the trial provided all chemotherapy was completed > 6 months prior and/or bone marrow transplant > 2 years prior to first day of study treatment
Chemotherapy must have been completed at least 4 weeks prior to initiation of study medication
Prior CNS directed radiation treatment completed within 3 weeks prior to registration
All prior chemotherapy completed at least three weeks before study treatment
Patients must have completed any previous surgery or radiotherapy >= 4 weeks prior to enrollment
The participant may have prior treatment for bladder tumor (excluding radiation therapy) provided that treatment:\r\n* Was completed greater than 30 days prior to the first dose of study agent
Prior radiation therapy is allowed but must have been completed >= 4 weeks prior to study entry; patients with history of prior radiation to the liver including radio-labeled microspheres cannot take part in this study
Completed at least one cycle of the treatment
Completed their last dose of chemotherapy or had their last cancer surgery more than 10 weeks, whichever came later, prior to randomization.
Have completed treatment greater than 4 weeks prior to enrollment.
Has completed the CS35 trial.
Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor), or radiotherapy must have been completed at least 14 days before administration of T-cells; prior immunotherapy with checkpoint blockade (i.e., PD1 inhibitor, PDL1 inhibitor, or CTL4-antagonist or similar agent) must have been completed more than 1 month before the T-cell infusion\r\n* Chemotherapy must have been completed at least 7 days prior to leukapheresis
Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor), or radiotherapy must have been completed at least 14 days prior to administration of T cells; continuation of hormonal therapy (i.e. for breast cancer) is acceptable; prior immunotherapy with checkpoint blockade (i.e. PD1 inhibitor, PDL1 inhibitor, or CTL4-antagonist or similar agent) must have been completed more than 1 month prior to the T cell infusion\r\n* Chemotherapy must have been completed at least 7 days prior to leukapheresis
Prior radiation therapy completed >= 4 weeks prior to enrollment
TURBT successfully completed
Prior chemotherapy for curative intent is permitted providing the cytotoxic chemotherapy was completed >= 12 months prior to enrollment; patients must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 30 days prior to registration; patient must not have brain metastases unless: (1) metastases have been treated and have remained controlled for at least two weeks following treatment, AND (2) patient has no residual neurological dysfunction off corticosteroids for at least 1 day; any radiation therapy completed prior to chemotherapy, except gamma-knife radiosurgery, 1 week prior to chemotherapy
Prior chemotherapy for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed >3 years ago. No further anti-cancer therapy after the previous AR targeted therapy and before inclusion. Prior docetaxel in hormone sensitive setting is allowed if completed >1 year before randomization. Prior immunotherapy is allowed.
Completed 24 weeks of treatment in Protocol 8400-401
Prior chemotherapy completed at least 3 weeks prior to study enrollment
Radiation therapy and surgery must be completed 4 weeks prior to therapy, except for limited field radiation therapy, which must be completed 2 weeks before therapy.
completed all treatment and follow-up through at least 12 weeks
Radiotherapy (RT) completed within 14 days prior to the first dose of study therapy.
Anti-cancer therapy (including conventional cytotoxic chemotherapy and/or biological therapy) and radiotherapy must be completed and any associated toxicities resolved to </= Grade 1 levels or baseline levels and at least 2 weeks must have elapsed before enrollment. Treatment with monoclonal antibodies must be completed at least 14 days before entry. Must have completed immunosuppressive medications or vaccinations before enrollment.
No prior systemic therapy or radiation therapy active against myeloma lasting more than four weeks duration; any prior therapy must be completed a minimum of 21 days before starting study drugs; enrollment of subjects who require radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy
Prior local radiotherapy is allowed if it is completed at least 4 weeks prior to the first dose of study drug and the subject has evaluable lesions not previously irradiated
Patients must have completed a course of radiation therapy and at least 2 adjuvant cycles of temozolomide for the phase 2 component.
Any prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least 6 weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients who have had prior monoclonal antibody therapy must have completed that therapy at least 3 half-lives of the antibody or 6 weeks ago; patients who have received more than a cumulative dose of 350 mg/m^2 of doxorubicin may be enrolled at the discretion of the coordinating center principal investigator (PI) after consultation with a cardiologist and if screening echocardiogram is normal
Prior treatment with an EGFR inhibitor is allowed if it was administered as part of definitive therapy for locally advanced disease and completed >/=1 year before study enrollment
Patients are candidates for stereotactic radiosurgery as determined by the treating radiation oncologist; intra-cranial tumors must measure 4 cm or less in greatest dimension; patients may have received prior neurosurgical resection(s) of intra-cranial metastases if their operation(s) was (were) completed at least 28 days prior to starting study drug; patients may have had prior whole brain radiation therapy (WBRT) if it was completed at least 1 month prior to study enrollment
Has completed any prior radiotherapy ? 4 weeks prior to randomization
Has completed any prior hormonal therapy ? 2 weeks prior to randomization
Prior cancer treatment must be completed at least 14 days prior to registration for protocol therapy and the patient must have recovered from the acute toxic effects of the regimen. With the exception of Bevacizumab treatment, which must be completed 30 days prior to registration for protocol therapy.
Prior systemic chemotherapy must be completed > 2 weeks of radioembolization
Patients must have completed prior (non-excluded) anti-cancer therapy (including surgery or chemotherapy or hepatic embolization/chemoembolization or radioactive isotopes i.e. yttrium 90) at least 4 weeks prior to day 1
Patients must have completed planned local therapy (i.e., definitive surgery and radiation therapy) and adjuvant chemotherapy for breast cancer prior to registration; in addition, any prior local therapy and adjuvant chemotherapy should be completed prior to participant completion of baseline Patient Reported Outcomes (PRO) instruments (i.e., Health Assessment Questionnaire [HAQ], PROMIS Physical Function, Functional Assessment of Cancer Therapy [FACT] Breast and Endocrine Symptoms [ES], etc.) and collection of optional blood for banking for future research
Have completed all surgery, chemotherapy and/or radiation therapy within the last 2-60 months
Prior treatment with thoracic radiotherapy completed > 4 weeks and =< 9 months prior to enrollment
PHASE I: Completed primary surgery, chemotherapy, and radiation
Have completed neurotoxic chemotherapy at least 3 months prior to enrollment
Have completed active cancer treatment at least 1 year prior to study enrollment
Completed preoperative therapy and are on their presurgical rest period
Have completed primary treatments (including surgery, radiation, and chemotherapy) 1-5 years prior to recruitment
Chemotherapy has already commenced or been completed
Completed local definitive treatment (i.e., surgical treatment, chemotherapy and/or radiation therapy)
Completed a minimum of 8 years of education
Have completed all cancer treatment (including surgery, chemotherapy and/or radiation) at least 4 months prior to enrollment
YBCS: Completed treatment with surgery, radiation and chemotherapy (if applicable)
Gynecologic cancer treatment (e.g., surgery, chemotherapy, radiation therapy) was completed within 5 years prior to date of enrollment
Treatment has been completed (except hormone therapy) for >= 90 days prior to registration
Have completed treatment with surgery, radiation, and/or chemotherapy
PATIENTS: Have completed surgery with no plans for chemotherapy
Child: child is in treatment remission and has completed intensive therapy
Completed in person pre–test counseling
Have completed their course of CTX
Diagnosis of cancer (any stage) for which active treatment (e.g., surgery, chemotherapy, and/or radiotherapy) has been completed within 2 months to 2 years
Completed treatment for stage 1-3 breast cancer at least two months but not more than 24 months prior to enrollment.
Radiation therapy (RT) completed >= 6 months
Women who have completed more than two rounds of chemotherapy
Completed all primary treatment
Completed initial regional and systemic treatment
Completed surgery
Completed active cancer treatment other than maintenance therapy >= 3 months ago
Surgical resection and axillary assessment, radiation therapy, and/or chemotherapy, as indicated, completed at least 3 months prior to enrollment
Have completed all forms of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer between 4 and 36 months prior to enrollment in the study; participants can be currently taking hormones (such as tamoxifen) or monoclonal antibodies (such as Herceptin)
Completed chemotherapy > 3 months prior to enrollment and no concurrent adjuvant therapy other than hormone manipulation therapy for breast cancer (confirmed by patient self-report on the Health History Questionnaire; if patient is unable to confirm whether or not she completed chemotherapy 3 months prior to enrollment, we will send a letter to her physician to confirm eligibility on this criterion)
Patients must have completed all primary chemotherapy and consolidation therapy (if administered) at least 6 weeks, and no more than 6 months and 2 weeks, prior to enrollment and must be in complete remission; consolidation therapy is defined as any chemotherapy or biological therapy used for a patient who has completed at least four courses of primary chemotherapy and had documented complete remission prior to initiation of such chemotherapy (chemo) or biological therapy
Patient must have completed cancer treatment >= 2 years prior to study enrollment
Completed appropriate surgical therapy to include:
Patients with history of cancer must be in remission, with surgery completed at least 6 months prior to enrollment and chemotherapy completed at least 1 year prior to enrollment (except for basal cell carcinoma of the skin)
Prior administration of anthracyclines is acceptable if therapy was completed > 6 months prior to study enrollment
No prior chemotherapy regimen; prior isotope therapy with strontium-89, samarium or radium-223 (RAD223) should be completed at least three months (12 weeks) prior to treatment start
Systemic corticosteroid or other immunosuppressive therapy should be washed out 2 weeks before apheresis and must be completed at least 2 weeks prior to pre-infusion lymphodepletive chemotherapy.
Must have completed radiotherapy at least 12 months prior to entry
Completed radiation therapy
Prior chemotherapy completed < 7 days prior to planned study entry
Prior therapy (chemotherapy, immunotherapy, radiotherapy) must be completed at least 2 weeks prior to infusion of radiolabeled antibody
Bilirubin =< 1.5 x ULN, completed within 2 weeks prior to start of protocol therapy
Laboratory studies must be completed within 28 days prior to pimonidazole administration
Prior definitive radiation therapy must have been completed at least 3 weeks before study drug administration
Any prior systemic therapy (e.g., chemotherapy, molecularly targeted agent, immunotherapy, etc.) or major surgery must have been completed at least 30 days (or as determined by the local requirement, whichever is longer), or at least 5 half lives for drugs with half lives of 6 days or longer prior to initiation of crizotinib treatment. Any prior radiation (except palliative) or minor surgeries/procedures must have been completed at least 2 weeks prior to the initiation of crizotinib treatment. Palliative radiation (? 10 fractions) must have been completed 48 hours prior to the initiation of crizotinib treatment. Any acute toxicity must have recovered to Grade ?1 (except alopecia).
Patient: Has completed surgical therapy
Colonoscopy not completed in the last 10 years
Sigmoidoscopy not completed in the last 5 years
Colonoscopy completed within the last 10 years
Sigmoidoscopy completed within the last 5 years
Prior local intravesical chemotherapy or immunotherapy is allowed if completed at least 4 weeks prior to the initiation of study treatment
Glioma patients must have completed chemoradiotherapy at least 12 weeks prior to screening and their baseline scan